A Phase 3 trial of OMS721 in IgA nephropathy.

Trial Profile

A Phase 3 trial of OMS721 in IgA nephropathy.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2017 According to Omeros Corporation media release, company is working with US FDA to finalize the protocol for this trial and expect to initiate the enrollment by end of the year 2017.
    • 16 Nov 2016 New trial record
    • 31 Oct 2016 According to an Omeros Corporation media release, company plans to initiate this trial in 2017 if fast track designation is granted by FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top